Trending News

#Covid-19 #Immunology / Virology & Vaccines #Research study #Vaccines

Is this the solution to increasing Covid-19 vaccine uptake?

The largest ever study of Covid-19 vaccine messaging shows that emphasising the personal benefits rather than collective of vaccination may be the most effective way to persuade people who are sceptical. Researchers from the University of Oxford, funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre… Read More

#Covid-19 #News #Trending News

#Biopharmaceutical #Covid-19 #Life sciences #Pharmaceutical research #Vaccines

ABPI chief stresses importance of research investment

The Chief Executive of the UK’s Association of the British Pharmaceutical Industry (ABPI), Richard Torbett, has stressed the importance of investment in research in response to the Queen’s Speech delivery. “The response to the pandemic has shown just how critical the UK’s pharmaceutical industry is to our country’s future and… Read More

#News #Trending News

#Clinical trials #Depression #Drug development #GlobalData

Novel antidepressant has blockbuster potential

Following the news that the Food and Drug Administration (FDA) has accepted Axsome Therapeutics’ new drug application (NDA) for its novel antidepressant therapy AXS-05 and granted it priority review, GlobalData commented that it would be “a blockbuster drug” by 2026, estimating global sales of approximately US$1.3 billion by 2029. Philippa… Read More

#News #Trending News

#Clinical trial #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Novavax initiates Covid-19 vaccine clinical trial crossover

Biotech company Novavax has announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s Covid-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax’ Phase IIb trial in South Africa and its pivotal Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Clinical trial #Covid-19 #Immunology / Virology & Vaccines

Oxford-AstraZeneca US vaccine trial data may be outdated

The Data and Safety Monitoring Board (DSMB) has notified the National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority (BARDA), and AstraZeneca that it is “concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial”. Trial volunteers received two standard… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Covid-19 #Drug delivery #Immunology / Virology & Vaccines

US trial data show Oxford-AstraZeneca vaccine is safe and 79% effective 

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca in the US, Chile and Peru has shown that the vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom. In the trial, which… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Biopharmaceutical #Covid-19 #Immunology / Virology & Vaccines #Sputnik

RDIF and Stelis Biopharma partner to vaccinate 100 million with Sputnik V

The Russian Direct Investment Fund (RDIF) and Stelis Biopharma, the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against COVID-19, sufficient to vaccinate 100 million people. Sputnik V is now approved for… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna doses first patients for its next generation COVID-19 vaccine

Moderna has announced that the first participants have been dosed in the Phase I study of mRNA-1283, the company’s next generation COVID-19 vaccine candidate. mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers Stéphane Bancel, Chief Executive Officer… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Drug delivery #Drug development #Drug discovery #Parkinson's

Researchers collaborate to design treatment for Parkinson’s disease

‍IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, AI-enabled drug designer, have announced a collaboration focussing on the discovery of novel drug candidates for the treatment of levodopa-induced dyskinesia… Read More

#Editor's Choice #News #Trending News

#Biotechnology #Life sciences #Pharma #Report #Therapeutics

Report shows growth in advanced therapeutics in Stockholm

A new report from Invest Stockholm on Advanced Therapeutics Manufacturing and Life Science in the Stockholm region showed that the sector has grown by 66% in the past four years. Collaboration between local tech and pharma industries are expected to further enhance Stockholm’s competitiveness and growth in the future. Both… Read More

#Editor's Choice #News #Trending News

#Antibodies #Biologics #Biologics / Biotechnology #Cell therapy

IONTAs and FairJourney antibody agreement with Quell Therapeutics

IONTAS and FairJourney Biologics (FJB) have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms. A diverse panel of novel target binders from IONTAS and FairJourney Biologics (FJB) will be used to identify antibodies to advance Quell’s engineered Treg cell therapy pipeline. Quell… Read More

#News #Trending News

#AstraZeneca #Biopharmaceuticals #Drug delivery #Drug development

Aptamer Group extends AstraZeneca collaboration

UK reagents and therapeutics developer, Aptamer Group has extended its current agreement with global biopharmaceutical company AstraZeneca. This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates. Optimers… Read More

#Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Professor Sarah Gilbert wins award for her work on the Oxford vaccine

The lead researcher on the Oxford vaccine team, Professor Gilbert is Professor of Vaccinology in the Nuffield Department of Medicine at the University of Oxford. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the… Read More

#Covid-19 #Editor's Choice #News #Trending News